Q4 2026
Released May 20, 2026, before the open
10-K filed May 20, 2026, 50 days after period end · 0001764013-26-000064
Q4 2026 · 10-K
derived · Computed from the longer spans the company filed.
Revenue—
Net Income-$147.86M-$147.86M derivedN/M vs Q4 2025N/M vs Q3 2026
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Cash Flowderived-$95,059,000N/M
Free Cash Flowderived-$95,067,000N/M
What the release said
The release
Same quarter
| Metric | Q4 2026dderived from reported figures | Q4 2025dderived from reported figures | Q4 2024dderived from reported figures | Q4 2023dderived from reported figures |
|---|---|---|---|---|
| Net Income | -$147.86M | -$106.45M | -$75.32M | -$59.43M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Immunovant, Inc. · CIK 1764013 · Engraved from SEC EDGAR